# HikariQ Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hikariq-health

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.hikariq.co.jp
- Total disclosed funding: $0.5M
- Latest round: Seed (Jan 27, 2023)
- Investors on record: 3

## About

Founded in 2021 and based in Tokyo, Japan, HikariQ Health, Inc. develops an antibody with a structure that enables the encapsulation of chemicals by changing antibody genes. As of January 2023, Kosuke Yoshii serves as the CEO of the company. In January 2023, HikariQ Health, Inc. raised JPY 65 million in seed funding from Business Creation Capital, Coral Capital, and the UT Founder's Association. The company develops original immunoassay methods and antibody drugs using its unique antibody technology. The firm provides Q-body, an antibody modification technology that adds a sensor function without impairing the performance of conventional immunoassay methods. Q-body is a single-chain variable region (scFv) or antigen-binding fragment (Fab) that combines an antibody's heavy chain variable region (VH) and light chain variable region (VL), along with a linker. The organisation plans to use the January 2023 funding for recruitment, research, and development.

## Funding rounds

- Seed, Jan 27, 2023, $0.5M — Jigyo Souzou Capital, Coral Capital, UT Founder's Association

## Investors

- Jigyo Souzou Capital (https://capitalatlas.ai/funds/jigyo-souzou-capital) — Seed
- Coral Capital — Seed
- UT Founder's Association — Seed